CG Oncology (CGON) Return on Sales (2023 - 2026)

CG Oncology's Return on Sales history runs 4 years deep, the most recent figure standing at 4.09% for Q1 2026.

• Quarterly Return on Sales rose 1933.0% year-over-year to 4.09% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1.71% (up 589.0% YoY) and the FY2025 annual result came in at 0.89%, up 83.0% from the prior year.
• Return on Sales was 4.09% for Q1 2026 at CG Oncology, down from 0.18% in the prior quarter.
• Across five years, Return on Sales topped out at 0.18% in Q4 2025 and bottomed at 165.51% in Q4 2023.
• A 4-year average of 23.26% and a median of 6.7% in 2025 frame the typical range for Return on Sales.
• Peak annual rise in Return on Sales reached 16481 bps in 2024, while the deepest fall reached 2817 bps in 2024.
• CG Oncology's Return on Sales stood at 165.51% in 2023, then soared by 100 bps to 0.7% in 2024, then soared by 74 bps to 0.18% in 2025, then slumped by 2191 bps to 4.09% in 2026.
• Business Quant data shows CGON's Return on Sales at 4.09% in Q1 2026, 0.18% in Q4 2025, and 1.41% in Q3 2025.